Navigation Links
Verenium to Present at Upcoming Conferences
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced James Levine, President and Chief Executive Officer, will present at two upcoming conferences.

Mr. Levine will present at the upcoming Barclays Capital Clean Solutions Conference as part of the "Biofuels" panel discussion scheduled from 1:30 – 3:00 p.m. ET on Thursday, May 19, 2011 in New York City.  Webcast information is unavailable at this time and will be posted to the "Investors" section of the Verenium website when available.

Mr. Levine will also present at the upcoming at the Stifel Nicolaus 2011 Cleantech Conference on Tuesday, May 24, 2011.  The presentation is expected to begin at 10:15 a.m. ET and will take place at the Omni Berkshire Place in New York City.  The live webcast may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com.  A webcast replay will be accessible for 30 days following the conference.  

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnersh
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
6. Verenium Announces First Commercial Cellulosic Ethanol Project
7. Verenium Announces Organizational Changes
8. Verenium Completes Amendment to 8% Senior Convertible Notes
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Announces Reverse Stock Split to Take Effect September 9
11. Verenium 1:12 Reverse Stock Split Takes Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Fla., Oct. 30 Pasteuria Bioscience, Inc., (http://www.pasteuriabio.com ... for agriculture,s largest unmet pest problem, announced,today that ... the new Chief,Executive Officer. Dr. Duncan has also ... succeeds Dr. Kelly Smith who will remain active ...
... NEW YORK and MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ... 30% interest in,Bacteria Bank Ltd. Bacteria Bank ... over ten,thousand cryogenically stored bacteria for use in ... headed by Dr. Karl Weiss a world,renowned bacteriologist. ...
... SAN DIEGO, Oct. 30 CryoCor, Inc. (Nasdaq:,CRYO), ... of cardiac,arrhythmias, announced today that Edward F. Brennan, ... Chief Financial Officer, are,scheduled to present at the ... York, NY on Tuesday, November 6, 2007 at ...
Cached Biology Technology:Pasteuria Bioscience Taps New CEO David N. Duncan 2Pasteuria Bioscience Taps New CEO David N. Duncan 3ICBS acquires 30% interest in Bacteria Bank Ltd. 2CryoCor to Present at CIBC World Markets 18th Annual Healthcare Conference 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... the most important paradigms of contemporary society, given the large ... and finally thrown way, this type of waste not being ... working in the recycling sector will be able to save ... new system developed by Tecnalia Research & Innovation. This ...
... COPENHAGEN, DENMARKNatural products marketed as plant growth enhancers ... typically produced by small companies with limited research ... nor have claims about product effectiveness been documented ... Copenhagen investigated the growth regulatory effect of Tea ...
... from Bishop Museum, Honolulu has found the world,s ... world,s smallest tetrapods (non-fish vertebrates). The frogs belong to the genus ... adults of the two new species - named Paedophryne dekot ... length. The study was published in the open access journal ...
Cached Biology News:1,200 recycling sector companies will save up to 10 percent thanks to a new system developed by Tecnalia 2Plant growth affected by tea seed powder 2World's smallest frogs discovered in New Guinea 2
... Shimadzu Biotech presents PsiPort Mass Directed ... review and data acquisition system designed ... for the life science and pharmaceutical ... designed specifically to simplify high throughput ...
... Anti-M13 polyclonal antibody was derived from rabbit ... particles.Recombinant protein domains such as antibody fragments ... pIII and displayed on phage using phagemid-based ... utilized in the Ph.D. libraries. Anti-M13 pIII ...
... The Rapid DNA Ligation Kit ... blunt-end DNA fragments in just ... Depending on the DNA ... concentration) or concatemeric (high DNA ...
... catalyzes the transfer of the ... 5-terminus of polynucleotides or to ... The enzyme, purified from recombinant ... to phosphorylate RNA, DNA and ...
Biology Products: